Pathologically activated therapeutics for neuroprotection - PubMed (original) (raw)
Review
doi: 10.1038/nrn2229.
Affiliations
- PMID: 17882256
- DOI: 10.1038/nrn2229
Review
Pathologically activated therapeutics for neuroprotection
Stuart A Lipton. Nat Rev Neurosci. 2007 Oct.
Erratum in
- Nat Rev Neurosci. 2007 Nov;8(11):2p following 903
Abstract
Many drugs that have been developed to treat neurodegenerative diseases fail to gain approval for clinical use because they are not well tolerated in humans. In this article, I describe a series of strategies for the development of neuroprotective therapeutics that are both effective and well tolerated. These strategies are based on the principle that drugs should be activated by the pathological state that they are intended to inhibit. This approach has already met with success, and has led to the development of the potentially neuroprotective drug memantine, an N-methyl-D-aspartate (NMDA)-type and glutamate receptor antagonist.
Similar articles
- The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS, Lipton SA. Chen HS, et al. J Neurochem. 2006 Jun;97(6):1611-26. doi: 10.1111/j.1471-4159.2006.03991.x. J Neurochem. 2006. PMID: 16805772 Review. - Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine.
Lipton SA, Chen HS. Lipton SA, et al. Cell Death Differ. 2004 Jan;11(1):18-20. doi: 10.1038/sj.cdd.4401344. Cell Death Differ. 2004. PMID: 14647237 No abstract available. - Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA. Lipton SA. Nat Rev Drug Discov. 2006 Feb;5(2):160-70. doi: 10.1038/nrd1958. Nat Rev Drug Discov. 2006. PMID: 16424917 Review. - The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W, Parsons CG. Danysz W, et al. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32. doi: 10.1002/gps.938. Int J Geriatr Psychiatry. 2003. PMID: 12973747 Review.
Cited by
- Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Noetzli M, Eap CB. Noetzli M, et al. Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9. Clin Pharmacokinet. 2013. PMID: 23408070 Review. - Calpains are downstream effectors of bax-dependent excitotoxic apoptosis.
D'Orsi B, Bonner H, Tuffy LP, Düssmann H, Woods I, Courtney MJ, Ward MW, Prehn JH. D'Orsi B, et al. J Neurosci. 2012 Feb 1;32(5):1847-58. doi: 10.1523/JNEUROSCI.2345-11.2012. J Neurosci. 2012. PMID: 22302823 Free PMC article. - Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.
Hansen KB, Wollmuth LP, Bowie D, Furukawa H, Menniti FS, Sobolevsky AI, Swanson GT, Swanger SA, Greger IH, Nakagawa T, McBain CJ, Jayaraman V, Low CM, Dell'Acqua ML, Diamond JS, Camp CR, Perszyk RE, Yuan H, Traynelis SF. Hansen KB, et al. Pharmacol Rev. 2021 Oct;73(4):298-487. doi: 10.1124/pharmrev.120.000131. Pharmacol Rev. 2021. PMID: 34753794 Free PMC article. Review. - Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases.
Nakamura T, Lipton SA. Nakamura T, et al. Cell Death Differ. 2011 Sep;18(9):1478-86. doi: 10.1038/cdd.2011.65. Epub 2011 May 20. Cell Death Differ. 2011. PMID: 21597461 Free PMC article. Review. - Implications of glial nitric oxide in neurodegenerative diseases.
Yuste JE, Tarragon E, Campuzano CM, Ros-Bernal F. Yuste JE, et al. Front Cell Neurosci. 2015 Aug 17;9:322. doi: 10.3389/fncel.2015.00322. eCollection 2015. Front Cell Neurosci. 2015. PMID: 26347610 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous